X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (20) 20
female (16) 16
humans (16) 16
oncology (15) 15
middle aged (13) 13
adult (12) 12
aged (12) 12
male (11) 11
cancer (9) 9
mutation (7) 7
analysis (5) 5
anilides - pharmacokinetics (5) 5
antineoplastic agents - pharmacokinetics (5) 5
melanoma (5) 5
melanoma - drug therapy (5) 5
melanoma - genetics (5) 5
metastatic melanoma (5) 5
proto-oncogene proteins b-raf - genetics (5) 5
pyridines - pharmacokinetics (5) 5
survival (5) 5
treatment outcome (5) 5
aged, 80 and over (4) 4
anilides - administration & dosage (4) 4
anilides - adverse effects (4) 4
antineoplastic agents - administration & dosage (4) 4
antineoplastic agents - adverse effects (4) 4
azetidines - administration & dosage (4) 4
basal-cell carcinoma (4) 4
disease-free survival (4) 4
inhibition (4) 4
metastasis (4) 4
pharmacology & pharmacy (4) 4
piperidines - administration & dosage (4) 4
pyridines - administration & dosage (4) 4
pyridines - adverse effects (4) 4
acid (3) 3
activation (3) 3
adsorption (3) 3
anilides - therapeutic use (3) 3
animals (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
blasting (3) 3
chemotherapy (3) 3
clavulanate (3) 3
double-blind method (3) 3
drug administration schedule (3) 3
heating (3) 3
hedgehog proteins - antagonists & inhibitors (3) 3
human homolog (3) 3
indoles - administration & dosage (3) 3
indoles - adverse effects (3) 3
lighting (3) 3
mechanical engineering (3) 3
medical prognosis (3) 3
metastases (3) 3
mutations (3) 3
neoplasm metastasis (3) 3
neoplasms - drug therapy (3) 3
patients (3) 3
pharmacokinetics (3) 3
potassium clavulanate (3) 3
pyridines - therapeutic use (3) 3
sulfonamides - administration & dosage (3) 3
sulfonamides - adverse effects (3) 3
time factors (3) 3
vemurafenib (3) 3
weapons (3) 3
administration, oral (2) 2
angiogenesis (2) 2
antineoplastic agents - blood (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
area under curve (2) 2
article (2) 2
azetidines - adverse effects (2) 2
biologic width (2) 2
biotechnology (2) 2
biotechnology & applied microbiology (2) 2
braf (2) 2
braf inhibitor (2) 2
cancer therapies (2) 2
cardiac & cardiovascular systems (2) 2
care and treatment (2) 2
cell cycle (2) 2
chemistry (2) 2
chromatography (2) 2
chromatography, liquid (2) 2
clinical trial results (2) 2
clinical trials (2) 2
creatine (2) 2
creatine kinase (2) 2
dabrafenib (2) 2
deaf-aid sets (2) 2
diarrhea (2) 2
dogs (2) 2
dose-response relationship, drug (2) 2
efficacy (2) 2
egfl7 (2) 2
electric communication technique (2) 2
electricity (2) 2
endothelial-cells (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 11/2014, Volume 371, Issue 20, pp. 1867 - 1876
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 09/2017, Volume 23, Issue 17, pp. 5238 - 5245
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2011, Volume 17, Issue 8, pp. 2502 - 2511
Journal Article
The Lancet Oncology, ISSN 1470-2045, 06/2019, Volume 20, Issue 6, pp. 849 - 861
Microsatellite-stable metastatic colorectal cancer is typically unresponsive to immunotherapy. This phase 3 study was designed to assess atezolizumab plus... 
DABRAFENIB | MEK | INHIBITION | ONCOLOGY | MICROSATELLITE INSTABILITY | TRAMETINIB | DEFICIENT | BRAF | COMBINATION | NIVOLUMAB | PD-1 | Analysis | Colorectal cancer | Metastasis
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 04/2014, Volume 54, Issue 4, pp. 368 - 374
Journal Article
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 06/2019, Volume 25, Issue 11, pp. 3239 - 3246
Previous investigations identified transcriptional signatures associated with innate resistance to anti-programmed cell death protein 1 therapy in melanoma.... 
Journal Article
The Oncologist, ISSN 1083-7159, 06/2018, Volume 23, Issue 6, pp. 654 - e58
经验总结 在此非小细胞肺癌II期试验中, EGFL7抗体联合贝伐单抗和化疗标准治疗缺乏疗效与在结直肠癌患者中观察到的缺乏获益的情况一致, 突出显示了在非选定人群中增强VEGF抑制效力的挑战。 今后有关EGFL7抗体等药物的工作应以抗血管生成药物的药效学和预测性生物标志物开发的进展为指导。 摘要 背景 .... 
EGFL7 | INHIBITION | VESSELS | ANGIOGENESIS | ONCOLOGY | GROWTH-FACTOR VEGF | ENDOTHELIAL-CELLS | Clinical Trial Results
Journal Article
The Oncologist, ISSN 1083-7159, 04/2017, Volume 22, Issue 4, pp. 375 - e30
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 05/2016, Volume 34, Issue 15, pp. 9528 - 9528
Conference Proceeding
Journal Article